These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25518318)

  • 1. Modified desensitization protocols for a pediatric patient with anaphylactic reaction to deferoxamine.
    Surapolchai P; Poachanukoon O; Satayasai W; Silapamongkonkul P
    J Med Assoc Thai; 2014 Aug; 97 Suppl 8():S217-22. PubMed ID: 25518318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful desensitization of a case with desferrioxamine hypersensitivity.
    Gülen F; Demir E; Tanaç R; Aydinok Y; Gulen H; Yenigün A; Can D
    Minerva Pediatr; 2006 Dec; 58(6):571-4. PubMed ID: 17093379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful desensitization of a child with desferrioxamine hypersensitivity.
    Patriarca G; Schiavino D; Nucera E; Pellegrino S; Valle D; Della Corte AM; Pagliari G
    J Investig Allergol Clin Immunol; 1995; 5(5):294-5. PubMed ID: 8574439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekend very high-dose intravenous deferoxamine in children with transfusional iron overload.
    Nelson SC; Hennessy JM; McDonough EA; Guck KL
    J Pediatr Hematol Oncol; 2006 Mar; 28(3):182-5. PubMed ID: 16679946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid desensitisation for desferrioxamine anaphylactic reaction.
    Miller KB; Rosenwasser LJ; Bessette JA; Beer DJ; Rocklin RE
    Lancet; 1981 May; 1(8228):1059. PubMed ID: 6112440
    [No Abstract]   [Full Text] [Related]  

  • 7. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T; Ferro G; Frontini V; Percolla S
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation and management of pediatric patients with anaphylactoid reactions to deferoxamine mesylate.
    Somech R; Seaban-Adel K; Atkinson A; Kirby-Allen M
    Ann Allergy Asthma Immunol; 2007 Dec; 99(6):575-6. PubMed ID: 18219844
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of high dose intravenous desferrioxamine for reduction of iron overload in sickle cell disease.
    Kalpatthi R; Peters B; Kane I; Holloman D; Rackoff E; Disco D; Jackson S; Laver JH; Abboud MR
    Pediatr Blood Cancer; 2010 Dec; 55(7):1338-42. PubMed ID: 20981690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a new method of administration of the iron chelating agent deferoxamine.
    Borgna-Pignatti C; Cohen A
    J Pediatr; 1997 Jan; 130(1):86-8. PubMed ID: 9003855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the prevention and treatment are changing thalassemia from a fatal to a chronic disease. experience from a Cyprus model and its use as a paradigm for future applications.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):287-95. PubMed ID: 19814674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desensitization treatment for anaphylactoid reactions to desferrioxamine in a pediatric patient with thalassemia.
    La Rosa M; Romeo MA; Di Gregorio F; Russo G
    J Allergy Clin Immunol; 1996 Jan; 97(1 Pt 1):127-8. PubMed ID: 8568125
    [No Abstract]   [Full Text] [Related]  

  • 13. Management and successful desensitization in methotrexate-induced anaphylaxis.
    Bouchireb K; Dodille A; Ponvert C; Gouraud F; Dubrel M; Brugières L
    Pediatr Blood Cancer; 2009 Feb; 52(2):295-7. PubMed ID: 18855892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
    Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
    Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaphylaxis to omeprazole: diagnosis and desensitization protocol.
    Confino-Cohen R; Goldberg A
    Ann Allergy Asthma Immunol; 2006 Jan; 96(1):33-6. PubMed ID: 16440530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy - deferasirox and deferoxamine - in thalassemia major patients in emerging countries with limited resources.
    Arandi N; Haghpanah S; Safaei S; Zahedi Z; Ashrafi A; Eatemadfar P; Zarei T; Radwan AH; Taher AT; Karimi M
    Transfus Med; 2015 Feb; 25(1):8-12. PubMed ID: 25801075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-Based Optimisation of Deferoxamine Chelation Therapy.
    Bellanti F; Del Vecchio GC; Putti MC; Cosmi C; Fotzi I; Bakshi SD; Danhof M; Della Pasqua O
    Pharm Res; 2016 Feb; 33(2):498-509. PubMed ID: 26555666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of deferoxamine (DFO) in transfusion-dependent β-thalassemia during pregnancy: A retrospective study.
    Piccioni MG; Capone C; Vena F; Del Negro V; Schiavi MC; D'Ambrosio V; Giancotti A; Smacchia MP; Brunelli R
    Taiwan J Obstet Gynecol; 2020 Jan; 59(1):120-122. PubMed ID: 32039778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desferrioxamine-related ocular toxicity: a case report.
    Simon S; Athanasiov PA; Jain R; Raymond G; Gilhotra JS
    Indian J Ophthalmol; 2012 Jul; 60(4):315-7. PubMed ID: 22824603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.